Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Lexicon Pharmaceuticals Inc to Provide a Regulatory Update on Sotagliflozin Conference Call Transcript

Mar 22, 2019 / 06:45PM GMT
Release Date Price: €6.63 (-5.15%)
Operator

Welcome to the Lexicon Pharmaceuticals Regulatory Update Call. (Operator Instructions) As a reminder, this call is being recorded today, March 22, 2019.

I will now turn the call over to Dr. Kimberly Lee, Head of Investor Relations and Corporate Strategy. Please go ahead.

Kimberly Lee
Lexicon Pharmaceuticals, Inc. - Head of IR & Corporate Strategy

Thank you, Dietra. Good afternoon, and welcome to Lexicon Pharmaceuticals regulatory update call in which we will discuss the FDA's issuance and the Complete Response Letter for sotagliflozin in type 1 diabetes.

Joining me on today's call are Lonnel Coats, Lexicon's President and Chief Executive Officer; Alex Santini, Executive Vice President and Chief Commercial Officer; Dr. Pablo Lapuerta, Executive Vice President and Chief Medical Officer; Dr. Praveen Tyle, Executive Vice President of Research and Development; and Jeff Wade, Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.

After our formal remarks, we will open the call up for Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot